

NYRx Education & Outreach Month in Review Newsletter

Volume 2, Issue 1 | January 10, 2025

About the NYRx E&O Team

The NYRx E&O team serves as a liaison between all stakeholders and NYRx to support care coordination. Clinical liaisons are trained to support and help solve complex pharmacy cases for:

- Managed Care Plans
- Case workers and NYS agencies
- Prescribers and pharmacies with questions regarding NYRx drug coverage, prior approval requirements, and NYRx enrolled pharmacies
- Complex care coordination for populations such as HIV/AIDS, Hemophilia, Foster Care Children, Serious Mental Illness, Substance Use Disorder, and Hepatitis C

NYRx E&O Publications

- [NYRx Drug Class Coverage Overview Benzodiazepine](#)
- [NYRx Drug Class Coverage Overview CNS Stimulants and Other Agents for ADHD](#)
- [NYRx Drug Class Coverage Overview GLP-1 Agonists](#)
- [NYRx Drug Class Coverage Overview Skeletal Muscle Relaxants](#)
- [NYRx Drug Class Coverage Overview: Antimigraine Agents](#)
- [NYRx Drug Class Coverage Overview: HIV Post-Exposure Prophylaxis Agents](#)
- [NYRx Drug Class Coverage Overview: Immunomodulators - Systemic and Benlysta](#)
- [NYRx Drug Class Coverage Overview: Pubertal Suppressants and Hormone Replacement Therapy for Treatment of Gender Dysphoria](#)
- [NYRx Drug Class Coverage Overview: Short Acting Opioids](#)

WELCOME!

We are excited to share with you what we have been up to this past month. Keep reading to learn about what's new, what's changed, and how we can help.

DECEMBER UPDATES

Preferred Drug List Updates

- [NYRx Preferred Drug List](#)
Check out the most recent updates, effective February 6, 2025.
- [NYRx Preferred Quick List](#)
Check out the most recent updates, effective December 20, 2024.

NYRx Formulary Updates

- [NYRx Preferred Diabetic Supply Program Resource](#)
Effective January 1, 2025, diabetic supplies manufactured by LifeScan have been removed from the NYRx Preferred Diabetic Supply List.
- [NYRx Formulary Update: Nucynta and Xtampza](#)
Effective January 1, 2025, Collegium Pharmaceutical, the manufacturer of Nucynta®, Nucynta ER®, and Xtampza® is no longer participating in the Medicaid Drug Rebate Program.
- [Discontinued Drug Coverage for Terminated Labelers per Medicaid National Drug Rebate Agreement](#)
Effective January 1, 2025, the following drug manufacturers voluntarily withdrew from participation in the Medicaid Drug Rebate Program (MDRP).

Claims Processing

- [Orthopedic Footwear Quantity Update for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies \(DMEPOS\) Providers](#)
Effective January 1, 2025, service limits for all adult orthopedic shoes, shoe additions, shoe inserts, and arch supports have aligned.
- [NYRx, The Medicaid Pharmacy Program: Top Edit Resource](#)
Point of sale rejections and how to resolve.

Reminders

- [NYRx Drug Class Coverage Overview Antipsychotics Second Generation](#)
Drugs in this drug class are subject to prior authorization (PA) requirements.
- [NYRx Drug Class Coverage Overview: Proton Pump Inhibitors](#)
Drugs in this drug class are subject to PA requirements.

MEET WITH THE TEAM

The NYRx E&O team is available to meet with you. Would you like to request a meeting with us? Click [here](#).



[NYRx E&O Website](#)
[NYRx E&O Mailbox](#)
[NYRx E&O YouTube Channel](#)
[New York Public Health Now Podcast](#)

NYRx E&O Call Center
 1-833-967-7310
 M – F, 8:00 AM – 5:00 PM ET
 Excludes Holidays